Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Byondis B.V.

Home Clinical Trial Sponsors and OrganizationsByondis B.V.

Byondis B.V.

Microweg 22, Nijmegen, Gelderland, Netherlands

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

6 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

14

77.8%

Phase 2

2

11.1%

Phase 3

1

5.6%

Trial Status Distribution

Active, not recruiting

6

33.3%

Completed

8

44.4%

Recruiting

4

22.2%

Clinical Trials

Trials sponsored by this organization (18)

A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

Active, not recruiting

May 20257 participants

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Active, not recruiting

Jun 202416 participants

A first-in-human dose escalation and expansion study with the SIRPa-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)

Active, not recruiting

May 202485 participants

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

Active, not recruiting

Mar 202417 participants

Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms.

Dec 202333 participants

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Mar 202231 participants

Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985

Jan 202248 participants

A study to evaluate the safety and efficacy of BYON5667 eye drops to reduce ocular toxicity in cancer patients treated with SYD985.

Active, not recruiting

May 2021205 participants

Page 1 of 3

Approvals

No approval data available

News

Novel HER2-Targeted Therapies Show Promise in Advanced Breast Cancer

- Trastuzumab duocarmazine significantly improves progression-free survival compared to physician's choice in pretreated HER2-positive metastatic breast cancer patients. - Combining eribulin with trastuzumab and pertuzumab demonstrates non-inferior progression-free survival versus taxanes in first-line HER2-positive advanced breast cancer. - Pertuzumab retreatment with trastuzumab and chemotherapy shows a significant overall survival benefit in HER2-positive locally advanced/metastatic breast cancer.

On this page

Overview
Clinical Trials18
Approvals
News1

Back to Organizations